Pathos Raises $237 Million: The Value of AI in Pharmaceutical Development Is Now Being Realized in R&D Decision-Making
On October 23, 2026, Pathos AI announced the completion of a $237 million Series E funding round, bringing its post-investment valuation to approximately $3 billion. The round was led by Bristol Myers Squibb (BMS) with participation from existing investors. The funds will be used to expand F...